# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-09-2024 | 03-31-2024 | 10-Q | |
2 | 03-01-2024 | 12-31-2023 | 10-K | |
3 | 11-03-2023 | 10-01-2023 | 10-Q | |
4 | 08-02-2023 | 07-02-2023 | 10-Q | |
5 | 06-02-2023 | 04-02-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.
Citigroup analyst Filippo Falorni reinstates Kenvue (NYSE:KVUE) with a Neutral and announces $21 price target.
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...
Kenvue Inc. (NYSE:KVUE) ("Kenvue") announced today the launch of a secondary underwritten public offering (the "Off...
-S-1